Pain syndrome in oncology. Possibilities of dexketoprofen administration

Abstract

Pain is an important problem in oncology patients. Depending on its intensity, for pain treatment, analgesics of different pharmacological classes are used. According to WHO recommendations, for nociceptive pain treatment in oncology patients, non-steroidal antiinflammatory drugs (NSAIDs), mild and potent opioids are the essential medications. If in pain formation along with the nociceptive pain component, a neuropathic one is present, antiepilepsy drugs, tricyclic antidepressants, local anesthetics are added. Apart from these medicines, adjuvants are used. These agents potentiate the analgesic endpoint of NSAIDs and opioids, correct their adverse effects. Often, intensive pain development is driven by bone metastases, which form in oncologic processes of different primary localization. Herewith, patients could suffer from constant as well as from paroxysmal, “breakthrough” pain. The efficacy of NSAIDs in oncology patients is due not only to analgesic effect but also to their action on inflammatory processes in areas of tumor formation and growth as well as in metastatic foci. Dexketoprofen trometamol is an effective and safe NSAID, a water-soluble salt of a dexketoprofen dextrorotatory stereoisomer. The preparation has a good lipid and water solubility. Thus, dexketoprofen trometamol can rapidly absorb, create therapeutic concentrations in blood serum, and penetrate through brain-blood barrier. It produces a significant and fast analgesic action in different diseases, which is related both to central analgesic mechanisms and to anti-inflammatory effect in peripheral tissues. Dexketoprofen trometamol efficacy is proven in bone pain related to oncological disease. The availability of intravenous solution and the prompt action at oral administration allow using the medicine for “breakthrough” pain. The medication significantly potentiates the action of mild and potent opioids at combined therapy, which allows to use opioid analgesics in lower doses.

Современные Концепции Возникновения Боли И Возможности Ее Преодоления В Общей Врачебной Практике

“…Лівообертальний стереоізомер (R-) практично не має фармакологічної активності, але при цьому його метаболіти відповідальні за розвиток небажаних ефектів кетопрофену. Хімічна ідентифікація правообертального стереоізомеру кетопрофену та встановлення його ролі в розвитку фармакологічного ефекту дозволили створити новий лікарський препарат -декскетопрофену троме-тамол, який являє собою водорозчинну сіль правообертального стереоізомеру кетопрофену [15].…”

Empirical determination of the degree of analgesic activity of some new 3-aminothieno[2,3-b]pyridines and 1,4-dihydropyridines based on a complex criterion

“…Relief of pain syndrome is a very important task in oncology. Pain is a very frequent and severe symptom of malignant neoplasms (Shtok 2016;Munoz-Farjas 2017;Kogoniya et al 2018;Pchelincev 2020). The number of patients with malignant neoplasms in the countries of the world, including Russia, is constantly increasing.…”